Comparative analysis of PEG-liposomes and RBCs-derived nanovesicles for anti-tumor therapy.

Lipid-based vesicular nanoparticles, for instance liposomes, conjugated with polyethylene glycol (PEG) have proven to be the closest to an ideal drug delivery vehicle, making way for several PEG-liposomes based nanomedicines in market. However, the synthetic nature of the nanomaterial poses a threat to stimulate immune system. Alternatively, nanovesicles derived from mammalian cells, such as RBCs, have gained interests as they may not elicit much immune response due to the presence of host specific self-recognition markers on their surface. While several reports demonstrating the superior efficacy of these naturally derived vesicles have come out in the last few years, a comparison with clinically established liposomes is still missing. Thus, we conducted an in-vitro and in-vivo comparative studies between PEG-Liposomes and nanovesicles (NVEs) derived from red blood cell (RBC) membrane with an aim to establish a biocompatible nanocarrier for efficient delivery of chemotherapeutic drugs and photothermal agents.